Keywords
Pulmonary Medicine ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

559 Search results.

Screening - GSK Milveterol COPD 100527

- 6/18/17 - 1 form, 9 itemgroups, 132 items, 1 language
Itemgroups: Inclusion/Exclusion criteria, Demography, Duration of Asthma, Vital Signs, 12-Lead Electrocardiogram, Pulmonary function, Hematology, Clinical Chemistry, Urinalysis
Study ID: 100527 Clinical Study ID: B2E100527 Study Title: A randomised, double blind, placebo controlled, parellel group study to examine the efficacy, safety, tolerability and systemic pharmacokinetic profile of repeated inhaled doses of GSK159797 Sponsor: GlaxoSmithKline Phase: phase 2 Study Recruitment Status: Completed Generic Name: milveterol Trade Name: Milveterol Study Indication: Pulmonary Disease, Chronic Obstructive

Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer NCT00549328 - Liver Events; Investigational Product (Liver); Alcohol Intake (Liver Alcohol); Medical Conditions; Pharmacokinetics (Liver); Liver Biopsy; Liver Imaging

- 8/2/19 - 1 form, 10 itemgroups, 102 items, 1 language
Itemgroups: Liver Events, Investigational Product (Liver) , Alcohol intake, Medical Conditions (Liver), Drug related liver disease conditions, Other liver disease conditions, Other medical conditions, Pharmacokinetics (Liver PK), Liver Biopsy, Liver imaging
Study ID: 109609 Clinical Study ID: 109609 Study Title: A Phase II, Non-randomized, Multi-center Study to Evaluate the Efficacy and Safety of Pazopanib (GW786034) in Subjects With Advanced Non-Small Cell Lung Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00549328 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: GW786034 Trade Name: Drug: Pazopanib Study Indication: Lung Cancer, Non-Small Cell

Eligibility Stage III Malignant Mesothelioma NCT02106559

- 7/26/19 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Photodynamic Therapy During Surgery in Treating Patients With Pleural Malignancy; ODM derived from: https://clinicaltrials.gov/show/NCT02106559

Eligibility Stage IV Non-Small Cell Lung Cancer NCT02451930

- 7/12/19 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC; ODM derived from: https://clinicaltrials.gov/show/NCT02451930

Eligibility Stage IV or Recurrent Non-Small Cell Lung Cancer NCT02041533

- 7/11/19 - 1 form, 3 itemgroups, 10 items, 1 language
Itemgroups: Criteria, Inclusion Criteria, Exclusion Criteria
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026); ODM derived from: https://clinicaltrials.gov/show/NCT02041533

Eligibility Stage IV Non-Small Cell Lung Cancer NCT02426658

- 7/10/19 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3; ODM derived from: https://clinicaltrials.gov/show/NCT02426658

Eligibility Stage III Non-small Cell Lung Cancer NCT02076282

- 7/10/19 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
MRI Optimization Study in Stage III NSCLC; ODM derived from: https://clinicaltrials.gov/show/NCT02076282

Eligibility Squamous Non Small Cell Lung Cancer NCT02403895

- 7/10/19 - 1 form, 2 itemgroups, 21 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
AZD2014 and Weekly Paclitaxel in Squamous NSCLC; ODM derived from: https://clinicaltrials.gov/show/NCT02403895

Eligibility Small Cell Lung Cancer NCT02500914

- 7/8/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT02500914

clinic internal medicine B SHIP-3 operational data lung function

- 7/4/19 - 1 form, 1 itemgroup, 58 items, 2 languages
Itemgroup: operational data lung function
operational data lung function form of SHIP Study (Study of Health in Pomerania), conducted by the University Medicine of Greifswald. SHIP unique domain name SHIP.SHIP3.IMB.LUF.LUFOPD. ODM derived from https://www.fvcm.med.uni-greifswald.de/dd_service/data_use_explore.php. Further information: http://www2.medizin.uni-greifswald.de/cm/fv/ship.html. Publication granted by Prof. Völzke. Reference: Völzke H, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40(2):294-307. PMID: 20167617 The English version of this form is under development.

Eligibility Respiratory Failure NCT02290548

- 6/30/19 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Effect of High-flow Nasal Oxygen on Extubation Outcome; ODM derived from: https://clinicaltrials.gov/show/NCT02290548

Eligibility Recurrent Non-small Cell Lung Cancer NCT02059889

- 6/27/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02059889